{"id":664633,"date":"2023-08-23T09:48:01","date_gmt":"2023-08-23T09:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=664633"},"modified":"2023-08-23T09:48:01","modified_gmt":"2023-08-23T09:48:01","slug":"pulmonary-hypertension-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-topadur-pharma-centessa","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pulmonary-hypertension-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-topadur-pharma-centessa_664633.html","title":{"rendered":"Pulmonary Hypertension Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Topadur Pharma, Centessa"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1692708041.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pulmonary Hypertension Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Topadur Pharma, Centessa\" src=\"https:\/\/www.abnewswire.com\/uploads\/1692708041.jpeg\" alt=\"Pulmonary Hypertension Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Topadur Pharma, Centessa\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Pulmonary Hypertension pipeline constitutes 80+ key companies continuously working towards developing 80+ Pulmonary Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-hypertension-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Pulmonary Hypertension Pipeline Insight, 2023<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Hypertension Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Pulmonary Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Pulmonary Hypertension Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Companies across the globe are diligently working toward developing novel Pulmonary Hypertension treatment therapies with a considerable amount of success over the years.&nbsp;<\/li>\n<li>Pulmonary Hypertension companies working in the treatment market are <strong>Topadur Pharma, Centessa Pharmaceuticals, Ribomic, Gmax Biopharm, ATXA Therapeutics, Aerami Therapeutics, PhaseBio Pharmaceuticals, Altavant Sciences, Respira Therapeutic, Pharmosa Biopharm, Merck,<\/strong> and others, are developing therapies for the Pulmonary Hypertension treatment&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Emerging Pulmonary Hypertension therapies in the different phases of clinical trials are-<strong> TOP V122, MGX292, RBM-011, Getagozumab, NTP42, AER-901, Pemziviptadil (PB1046), Rodatristat Ethyl, RT234, L606, Sotatercept,<\/strong> and others are expected to have a significant impact on the Pulmonary Hypertension market in the coming years.&nbsp;&nbsp;&nbsp;<\/li>\n<li><strong>In March 2022, Acceleron Pharma<\/strong> initiated a Phase 3, randomized, double-blind,placebo-controlled study to evaluate Sotatercept when added to background pulmonary arterial hypertension(PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients.<\/li>\n<li><strong>The United States Food and Drug Administration (FDA)<\/strong> has granted Orphan Drug designationandBreakthroughTherapy designation to sotatercept for the treatment of PAH. The European Medicines Agency (EMA) hasgranted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pulmonary Hypertension Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Elevated pulmonary vascular resistance is a defining characteristic of the broad group of illnesses known as pulmonary hypertension. Patients frequently exhibit vague symptoms such as increasing weakness and dyspnea with exertion. The management of symptoms and the therapy of underlying disorders are the main goals of treatment for the progressive disease known as pulmonary hypertension.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Pulmonary Hypertension Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-hypertension-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/pulmonary-hypertension-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Pulmonary Hypertension Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>TOP V122:<\/strong> Topadur Pharma<\/li>\n<li><strong>MGX292:<\/strong> Centessa Pharmaceuticals<\/li>\n<li><strong>RBM-011:<\/strong> Ribomic<\/li>\n<li><strong>Getagozumab:<\/strong> Gmax Biopharm<\/li>\n<li><strong>NTP42:<\/strong> ATXA Therapeutics<\/li>\n<li><strong>AER-901:<\/strong> Aerami Therapeutics<\/li>\n<li><strong>Pemziviptadil (PB1046):<\/strong> PhaseBio Pharmaceuticals<\/li>\n<li><strong>Rodatristat Ethyl:<\/strong> Altavant Sciences<\/li>\n<li><strong>RT234:<\/strong> Respira Therapeutic<\/li>\n<li><strong>L606:<\/strong> Pharmosa Biopharm<\/li>\n<li><strong>Sotatercept:<\/strong> Merck<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pulmonary Hypertension Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Pulmonary Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pulmonary Hypertension Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Pulmonary Hypertension Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pulmonary Hypertension Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Pulmonary Hypertension Assessment by Product Type<\/li>\n<li>Pulmonary Hypertension By Stage and Product Type<\/li>\n<li>Pulmonary Hypertension Assessment by Route of Administration<\/li>\n<li>Pulmonary Hypertension By Stage and Route of Administration<\/li>\n<li>Pulmonary Hypertension Assessment by Molecule Type<\/li>\n<li>Pulmonary Hypertension by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Pulmonary Hypertension Report covers around 80+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I)<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Pulmonary Hypertension product details are provided in the report. Download the Pulmonary Hypertension pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-hypertension-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Pulmonary Hypertension therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Pulmonary Hypertension Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Pulmonary Hypertension are &#8211; <strong><em>Arena Pharmaceuticals, Bayer AG., Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc., Johnson &amp; Johnson (Actelion Pharmaceuticals, Ltd.), Merck &amp; Co. Inc., Novartis International AG, and others.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pulmonary Hypertension Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Pulmonary Hypertension pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Hypertension with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Hypertension Treatment.<\/li>\n<li>Pulmonary Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Pulmonary Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Hypertension market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-hypertension-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Pulmonary Hypertension drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Pulmonary Hypertension Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rising prevalence of Pulmonary Hypertension worldwide, increasing investment for healthcare infrastructure, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Hypertension Market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pulmonary Hypertension Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>However, high cost associated with the treatment of Pulmonary Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Hypertension Market growth.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Pulmonary Hypertension Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage: Global<\/strong><\/li>\n<li><strong>Key Pulmonary Hypertension Companies:<\/strong> Topadur Pharma, Centessa Pharmaceuticals, Ribomic, Gmax Biopharm, ATXA Therapeutics, Aerami Therapeutics, PhaseBio Pharmaceuticals, Altavant Sciences, Respira Therapeutic, Pharmosa Biopharm, Merck, and others<\/li>\n<li><strong>Key Pulmonary Hypertension Therapies:<\/strong> TOP V122, MGX292, RBM-011, Getagozumab, NTP42, AER-901, Pemziviptadil (PB1046), Rodatristat Ethyl, RT234, L606, Sotatercept, and others<\/li>\n<li><strong>Pulmonary Hypertension Therapeutic Assessment:<\/strong> Pulmonary Hypertension current marketed and Pulmonary Hypertension emerging therapies<\/li>\n<li><strong>Pulmonary Hypertension Market Dynamics: Pulmonary Hypertension market drivers and Pulmonary Hypertension market barriers&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-hypertension-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Pulmonary Hypertension Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Pulmonary Hypertension Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Pulmonary Hypertension Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Pulmonary Hypertension Overview<\/p>\n<p style=\"text-align: justify;\">4. Pulmonary Hypertension- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Pulmonary Hypertension Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Pulmonary Hypertension Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify;\">7. Pulmonary Hypertension Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8. Pulmonary Hypertension Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">9. Pulmonary Hypertension Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Pulmonary Hypertension Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Pulmonary Hypertension Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Pulmonary Hypertension Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Pulmonary Hypertension Key Products<\/p>\n<p style=\"text-align: justify;\">15. Pulmonary Hypertension Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16 . Pulmonary Hypertension Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Pulmonary Hypertension Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Pulmonary Hypertension Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pulmonary-hypertension-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-topadur-pharma-centessa\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pulmonary-hypertension-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-topadur-pharma-centessa\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Pulmonary Hypertension pipeline constitutes 80+ key companies continuously working towards developing 80+ Pulmonary Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pulmonary-hypertension-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-topadur-pharma-centessa_664633.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-664633","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/664633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=664633"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/664633\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=664633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=664633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=664633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}